Call for 5 PhD Fellowships in Marie Skłodowska-Curie Innovative Training Network, to identify sel...

University of Copenhagen
September 21 2017
Position Type
Full Time
Organization Type

The PhD fellowship are part of the EU-funded project, SAFER. This is an ambitious interdisciplinary European Industrial Doctorates (EID) programme under the Horizon 2020 Marie Skłodowska-Curie Actions (MSCA-ITN-EID, Grant agreement: 765657), which offers positions with competitive salaries and family allowances. PhD students will obtain ample scientific, business and transferrable skills at excellent research environments meriting themselves for international academic or industrial careers.

The project starts 1st of February 2018 and lasts for 3 years. The positions require mobility as all students will first train at the University of Copenhagen (Denmark), and subsequently continue their research in a company; ENAMINE (Kiev, Ukraine) or SARomics (Lund, Sweden). Being a part of the network, the PhD fellows will participate in annual network meetings and training events across Europe. The students will be enrolled in the Graduate School of Health and Medical Sciences and affiliated to the graduate programme in pharmaceutical sciences, the Drug Research Academy PhD school at UCPH.

Training Programme

  • Research training activities, performed locally, leading to award of the PhD title.

  • Scientific/technical training courses and activities performed locally and at the project level to train the ESRs PhD students in scientific topics, advanced technology and methodologies necessary for the project implementation.

  • Transferable skills training to prepare the ESRs for an academic or industrial career will be provided through local and joint training courses.

  • Scientific events, such as one kick-off and 3 annual project meetings as well as regular with workshops

  • Teaching and dissemination of your research

Scientific goal

The ultimate scientific goal for the SAFER program is to gain molecular understanding and improve selectivity in treatments of CNS-related disorders. This will be done with a particular focus on the serotonin 5-HT2A receptor - the primary target for many pharmaceuticals and hallucinogens. SAFER will design and prepare ligands for the receptor, generate and cross-interpret pharmacology and crystallographic data, and construct computational mechanistic models and databases that can explain and guide further experiments. This is fundamental to understand the biological and therapeutic effects, and to develop safer drugs.


This job comes from a partnership with Science Magazine and Euraxess